Seasonal Flu Shot Buyer's Guide
(for H1N1 Flu Shot click here)
Mercury Levels
Recipient's Age
Flu Shot or Mist
The domain is for sale >
Contact John Deneen for more info.

Contains Mercury: thimerosal preservative
Patient Age: 18 years and older
Shot or Mist: shot
Manufacturer: Glaxo Smith Kline
Brand: FluLaval
Safe If Pregnant: consult your physician

FLULAVAL is a trivalent, split-virion, inactivated influenza virus vaccine prepared from virus propagated in the allantoic cavity of embryonated hens’ eggs. Each of the influenza virus strains is produced and purified separately.

Known systemic hypersensitivity reactions to egg proteins, or any other component of FLULAVAL, or life threatening reaction to previous influenza vaccination.

Asverse Reactions
  • Most common (greater than 10%) local adverse events were pain, redness, and/or swelling at the injection site.
  • Most common (greater than 10%) systemic adverse events were headache, fatigue, myalgia, low grade fever, and malaise.
Drug Interactions
  • Do not mix with any other vaccine in the same syringe or vial.
  • Immunosuppressive therapies may reduce immune responses to FLULAVAL.
Use In Specific Populations
  • Safety and effectiveness of FLULAVAL have not been established in pregnant women, nursing mothers, and children.
  • Geriatric Use: Antibody responses were lower in geriatric subjects than in younger subjects.
Warnings And Precautions
  • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLULAVAL should be based on careful consideration of the potential benefits and risks.
  • If FLULAVAL is administered to immunocompromised persons, including individuals receiving immunosuppressive therapy, the expected immune response may not be obtained.
  • As with other intramuscular injections, FLULAVAL should be given with caution in individuals with bleeding disorders such as hemophilia or on anticoagulant therapy to avoid the risk of hematoma following the injection.
  • Prior to administration, the healthcare provider should review the patient’s immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment, including epinephrine, and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
  • Vaccination with FLULAVAL may not protect all susceptible individuals.
Nursing Mothers
It is not known whether FLULAVAL is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when FLULAVAL is administered to a nursing woman.

Pediatric Use
Safety and effectiveness of FLULAVAL in pediatric patients have not been established.
Dosage Information:
FLULAVAL is a suspension in 5-mL multi-dose vials containing 10 doses (each dose is 0.5 mL).
  • Each 0.5-mL dose contains 15 micrograms (mcg) of influenza virus hemagglutinin (HA) of each of the following 3 strains: A/Brisbane/59/2007 (H1N1)-like virus (A/Brisbane/59/2007 IVR-148), A/Brisbane/10/2007 (H3N2)-like virus (A/Uruguay/716/2007 NYMC X-175C), and B/Florida/4/2006-like virus (B/Florida/4/2006).
  • Thimerosal, a mercury derivative, is added as a preservative. Each 0.5 mL dose contains 25 mcg mercury.

    Copyright © 2014 All rights reserved.
 Home  |  Product Links